These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 27777775)

  • 1. Acute visual loss after ipilimumab treatment for metastatic melanoma.
    Wilson MA; Guld K; Galetta S; Walsh RD; Kharlip J; Tamhankar M; McGettigan S; Schuchter LM; Fecher LA
    J Immunother Cancer; 2016; 4():66. PubMed ID: 27777775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
    Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Başsorgun I; Coşkun HŞ
    J Oncol Pharm Pract; 2016 Jun; 22(3):533-6. PubMed ID: 25694346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Acutely induced diabetes mellitus in a 63-year-old female after treatment with ipilimumab for metastatic melanoma].
    Jørgensen LB; Yderstræde K
    Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.
    Pushkarevskaya A; Neuberger U; Dimitrakopoulou-Strauss A; Enk A; Hassel JC
    J Immunother; 2017 Sep; 40(7):282-285. PubMed ID: 28604554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.
    Jung M; Lee J; Kim TM; Lee DH; Kang JH; Oh SY; Lee SJ; Shin SJ
    Cancer Res Treat; 2017 Jan; 49(1):44-53. PubMed ID: 27121719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma.
    Ariyasu H; Inaba H; Ota T; Yamaoka H; Furukawa Y; Iwakura H; Doi N; Yamamoto Y; Akamizu T
    In Vivo; 2018; 32(2):345-351. PubMed ID: 29475919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenging Cases: Management of Immune-Related Toxicity.
    Weber JS
    Am Soc Clin Oncol Educ Book; 2018 May; 38():179-183. PubMed ID: 30231403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.
    Garcia CA; El-Ali A; Rath TJ; Contis LC; Gorantla V; Drappatz J; Davar D
    J Immunother Cancer; 2018 Aug; 6(1):83. PubMed ID: 30170622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
    Subudhi SK; Aparicio A; Gao J; Zurita AJ; Araujo JC; Logothetis CJ; Tahir SA; Korivi BR; Slack RS; Vence L; Emerson RO; Yusko E; Vignali M; Robins HS; Sun J; Allison JP; Sharma P
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11919-11924. PubMed ID: 27698113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
    Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
    Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.
    de Moel EC; Rozeman EA; Kapiteijn EH; Verdegaal EME; Grummels A; Bakker JA; Huizinga TWJ; Haanen JB; Toes REM; van der Woude D
    Cancer Immunol Res; 2019 Jan; 7(1):6-11. PubMed ID: 30425107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN; Mukkamalla SKR; Armenio VA
    J Immunother Cancer; 2017 Dec; 5(1):97. PubMed ID: 29254501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipilimumab-induced hypophysitis, a single academic center experience.
    Snyders T; Chakos D; Swami U; Latour E; Chen Y; Fleseriu M; Milhem M; Zakharia Y; Zahr R
    Pituitary; 2019 Oct; 22(5):488-496. PubMed ID: 31327112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Mayo Clinic Experience With the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab.
    Ruff MW; Mauermann ML
    Neurologist; 2018 May; 23(3):98-99. PubMed ID: 29722744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients.
    Garcia-Neuer M; Marmarelis ME; Jangi SR; Luke JJ; Ibrahim N; Davis M; Weinberg J; Donahue H; Bailey N; Hodi FS; Buchbinder EL; Ott PA
    Cancer Immunol Res; 2017 Apr; 5(4):286-291. PubMed ID: 28373217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
    Chakravarti N; Ivan D; Trinh VA; Glitza IC; Curry JL; Torres-Cabala C; Tetzlaff MT; Bassett RL; Prieto VG; Hwu WJ
    Melanoma Res; 2017 Feb; 27(1):24-31. PubMed ID: 27768639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Severe ipilimumab-induced ulcerative colitis remitting after infliximab therapy and secondary switching with pembrolizumab].
    Yelehe-Okouma M; Granel-Brocard F; Hudziak H; Schmutz JL; Gillet P
    Therapie; 2018; 73(3):291-293. PubMed ID: 29203065
    [No Abstract]   [Full Text] [Related]  

  • 20. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
    Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
    Front Immunol; 2018; 9():411. PubMed ID: 29552014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.